Pain Management & Targeted Delivery
Nanocarrier platforms for localised relief from neuropathic and arthritic pain — without systemic side effects.
A suite of topical and nasal nanocarrier systems designed to precisely deliver analgesic molecules to the site of action, bypassing systemic exposure and its associated side effects.
Key platforms include a topical nanocarrier cream for amitriptyline targeting peripheral neuropathic pain (inflammatory arthritis, neuralgia), a micellar spray and gel for diclofenac diethylamine with effects superior to marketed products in preclinical analgesia and arthritis models, and a nasal spray for nose-to-brain delivery of a novel CRMP2 SUMOylation inhibitor (Molecule 194) that selectively attenuates NaV1.7 channel activity.
A non-invasive intranasal CBD nanocarrier platform — formulated with USFDA-approved excipients — addresses the challenges of CBD's poor stability and bioavailability for CNS pain management.
All systems are extensively tested in validated preclinical models of central and peripheral neuropathic pain, with effects demonstrated superior to existing market treatments.
Patents
- PCT/IN2025/050119 — Mixed Micelles for Drug Delivery
- 202511007805 — Mixed Micelles for Drug Delivery (India)
- 202411002254 — Nanomicellar Composition for High Permeation and Extended-Release